# Repligen Corporation – Consensus ‘buy’ rating and -1.6% Downside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-1.6-downside-potential/4121136114
- Published: 2023-12-15T14:01:27+00:00
- Author: Charlotte Edwards

**Repligen Corporation** with ticker code (RGEN) have now 13 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between $210.00 and $148.00 suggesting
an average Analsyt target price of $172.15. Given that the stocks previous close
was at $174.92 this indicates there is a potential downside of -1.6%. The 50 day
MA is $150.07 and the 200 moving average now moves to $160.08. The company has a
market cap of 10.07B. The stock price for the company is currently $180.41 USD

 The potential market cap would be $9,913,143,170 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 89.31, revenue per share of $12.04 and a 2.08% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on:
